Regentis Biomaterials Ltd.

Regentis Biomaterials Ltd. is a regenerative medicine company that develops and commercializes tissue repair solutions in the United States. Its products include Gelrin, a platform based on a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue, and GelrinC, a cell-free, off-the-shelf hydrogel in Phase II clinical trials for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.